Wowgut-L Tablet SR is a combination pharmaceutical formulation containing Levosulpiride 75 mg and Rabeprazole 20 mg, designed to manage gastrointestinal disorders characterized by dyspepsia, gastroesophageal reflux disease (GERD), and functional dysmotility. Levosulpiride, a selective dopamine D2 receptor antagonist, exerts prokinetic and antiemetic effects by enhancing gastric motility and accelerating gastric emptying, thereby alleviating symptoms such as nausea, vomiting, bloating, and abdominal discomfort. Rabeprazole, a proton pump inhibitor (PPI), inhibits the H+/K+ ATPase enzyme system in gastric parietal cells, leading to a significant reduction in gastric acid secretion. This dual action effectively addresses both motility disturbances and acid-related mucosal damage, providing symptomatic relief and promoting mucosal healing. Wowgut-L Tablet SR is indicated for patients with acid peptic disorders accompanied by impaired gastric motility, including GERD, non-ulcer dyspepsia, and functional dyspepsia. The sustained-release formulation ensures prolonged therapeutic plasma concentrations, enhancing efficacy and patient compliance. It should be used under medical supervision, with caution advised in patients with known hypersensitivity to either component, and in those with severe hepatic or renal impairment. Potential side effects may include headache, dizziness, diarrhea, and rare extrapyramidal symptoms. Regular monitoring and adherence to prescribed dosage are essential for optimal therapeutic outcomes.